Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
received:
11
05
2021
revised:
26
08
2021
accepted:
21
09
2021
pubmed:
29
9
2021
medline:
8
4
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
We investigated whether organoids can be generated from resected tumors of patients who received eight cycles of neoadjuvant FOLFIRINOX chemotherapy before surgery, and evaluated the sensitivity/resistance of these surviving cancer cells to cancer therapy. We generated a library of 10 pancreatic ductal adenocarcinoma (PDAC) organoid lines: five each from treatment-naïve and FOLFIRINOX-treated patients. We first assessed the histologic, genetic, and transcriptional characteristics of the organoids and their matched primary PDAC tissue. Next, the organoids' response to treatment with single agents-5-FU, irinotecan, and oxaliplatin-of the FOLFIRINOX regimen as well as combined regimen was evaluated. Finally, global mRNA-seq analyses were performed to identify FOLFIRINOX resistance pathways. All 10 patient-derived PDAC organoids recapitulate histologic, genetic, and transcriptional characteristics of their primary tumor tissue. Neoadjuvant FOLFIRINOX-treated organoids display resistance to FOLFIRINOX (5/5), irinotecan (5/5), and oxaliplatin (4/5) when compared with treatment-naïve organoids (FOLFIRINOX: 1/5, irinotecan: 2/5, oxaliplatin: 0/5). 5-Fluorouracil treatment responses between naïve and treated organoids were similar. Comparative global transcriptome analysis of treatment-naïve and FOLFIRINOX samples-in both organoids and corresponding matched tumor tissues-uncovered modulated pathways mainly involved in genomic instability, energy metabolism, and innate immune system. Resistance development in neoadjuvant FOLFIRINOX organoids, recapitulating their primary tumor resistance, suggests continuation of FOLFIRINOX therapy as an adjuvant treatment may not be advantageous for these patients. Gene-expression profiles of PDAC organoids identify targetable pathways involved in chemoresistance development upon neoadjuvant FOLFIRINOX treatment, thus opening up combination therapy possibilities.
Identifiants
pubmed: 34580113
pii: 1078-0432.CCR-21-1681
doi: 10.1158/1078-0432.CCR-21-1681
pmc: PMC9401459
doi:
Substances chimiques
folfirinox
0
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6602-6612Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Ann Surg Oncol. 2020 Oct;27(10):3939-3947
pubmed: 32266574
Gut. 2015 Nov;64(11):1783-9
pubmed: 25636698
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Biochem Biophys Res Commun. 2016 Apr 22;473(1):174-180
pubmed: 27012213
Cell. 2020 Apr 16;181(2):424-441.e21
pubmed: 32234521
J Clin Oncol. 2016 Jul 20;34(21):2541-56
pubmed: 27247221
Asian Pac J Cancer Prev. 2014;15(4):1823-9
pubmed: 24641416
Nat Mater. 2021 Feb;20(2):156-169
pubmed: 32807924
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Heliyon. 2018 Dec 17;4(12):e01055
pubmed: 30582059
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Elife. 2016 Feb 23;5:
pubmed: 26902720
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Crit Rev Oncol Hematol. 2017 Jun;114:139-152
pubmed: 28477742
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
Nat Commun. 2021 Feb 22;12(1):1213
pubmed: 33619254
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Cell Stem Cell. 2018 Mar 1;22(3):454-467.e6
pubmed: 29337182
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Nat Biotechnol. 2017 Jun 7;35(6):500-502
pubmed: 28591115
Clin Cancer Res. 2015 Jul 1;21(13):2916-23
pubmed: 25838394
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Science. 2019 Jun 07;364(6444):952-955
pubmed: 31171691
Adv Biol Regul. 2018 May;68:77-87
pubmed: 29221990